Syntax II


SYNTAX II is a European multicenter single-arm study investigating the effectiveness of contemporary PCI in 450 patients with de novo three-vessel disease (3VD) following Heart Team (interventional cardiologist and cardiac surgeon) consensus - applying the SYNTAX Score II and incorporating pressure wire assessment (ischemia-driven revascularization) and IVUS guidance (to optimize DES deployment).

The Principal Investigators are Dr. Javier Escaned (Spain) and Professor Adrian Banning (United Kingdom).  

The European Cardiovascular Research Institute (ECRI) is the Sponsor for the SYNTAX II trial. ECRI is being supported by scientific grants from Boston Scientific Corporation and Volcano Corporation.

The SYNTAX II trial is registered at